Overview

This trial is active, not recruiting.

Condition acute lung injury(ali)
Sponsor Taipei Medical University WanFang Hospital
Start date January 2011
End date December 2011
Trial size 20 participants
Trial identifier NCT01373203, 99077

Summary

The important character of acute lung injury (ALI) is alveolar capillary membrane damage caused by different diseases, such as sepsis, trauma and shock. One of the important pathological stages is the varying degrees of interstitial fibrosis and semi-permeable alveolar membrane fibrosis. It has been proved that CXCL12/SDF-1 (stromal cell-derived factor-1) induces fibrocyte migration, and promotes fibrosis progression. Study indicated that inhibition of TLR4 receptor signaling pathway improves fibrosis progression induced by ALI, however, the role of fibrocyte in ALI is still unclear. The fibrocytes was significantly increased in asthmatic patients with pulmonary fibrosis, which companies with increased CTGF expression. Therefore, this project assumes that fibrocyte will differentiation to fibroblast/myofibroblast in patient with acute lung injury, which in turn leads to progression of fibrosis. The central hypothesis of this project is that peripheral progenitor cell fibrocytes play an important role in alveolitis caused by acute lung injury. The overall objective of this project is to study the role of fibrocytes in acute lung injury.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case-only

Eligibility Criteria

Male or female participants at least 20 years old.

Inclusion Criteria: - Acute Lung Injury patients - Above 20 years old - Bilateral lung infiltrates - PaO2/FiO2<300mmHg - PCWP<18mmHg Exclusion Criteria: - Pregnant women - Under 20 years old - Hb<8.0mg/dl

Additional Information

Official title The Role of Fibrocytes in Acute Lung Injury
Principal investigator Kuan-Jen Bai
Trial information was received from ClinicalTrials.gov and was last updated in June 2011.
Information provided to ClinicalTrials.gov by Taipei Medical University WanFang Hospital.